About
John Clarke has a 35 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success. John led the firm’s investment in Cubist Pharmaceuticals (Nasdaq:CBST), Momenta Pharmaceuticals (Nasdaq:MNTA), Alnylam Pharmaceuticals (Nasdaq:ALNY), Sirtris Pharmaceuticals (Nasdaq:SIRT) and Verastem (Nasdaq:VSTM). John also spearheaded Cardinal’s investment in and served as a director for: TechRx Corporation (acquired by NDCHealth) and Visicu (Nasdaq:EICU – acquired by Phillips Electronics). John currently serves on the Board of Directors for Cardinal portfolio companies Abide Therapeutics, aTyr Pharma, Ivenix , and Vividion Therapeutics, as well as Alnylam Pharmaceuticals. John entered the venture industry in 1982 with DSV Partners, a pioneer venture capital fund formed in 1968. John led DSV’s heal
Position in the VCSift Database
- • 3 investors at Cardinal Partners are tracked.
- • 11 investors hold the General Partner & Founder role in VCSift. John Clarke is one of them.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
Contact Information
Find more investors like John
Search Investors